NO320702B1 - Nye cyklonbutendionforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents
Nye cyklonbutendionforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO320702B1 NO320702B1 NO20014945A NO20014945A NO320702B1 NO 320702 B1 NO320702 B1 NO 320702B1 NO 20014945 A NO20014945 A NO 20014945A NO 20014945 A NO20014945 A NO 20014945A NO 320702 B1 NO320702 B1 NO 320702B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- ethyl
- amino
- piperidinyl
- dione
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 70
- 238000000034 method Methods 0.000 title claims description 49
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 59
- 230000008569 process Effects 0.000 claims description 44
- 230000002792 vascular Effects 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 14
- 230000008694 endothelial dysfunction Effects 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- -1 methylenedioxy Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000003143 atherosclerotic effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- JKWQHCSGMTWRIQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NCCC2=N1 JKWQHCSGMTWRIQ-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 description 62
- 239000000758 substrate Substances 0.000 description 56
- 238000002844 melting Methods 0.000 description 46
- 230000008018 melting Effects 0.000 description 46
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- IPUVCDRGLVFLPW-UHFFFAOYSA-N 2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1CCOC1=CC=C(F)C=C1 IPUVCDRGLVFLPW-UHFFFAOYSA-N 0.000 description 13
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
- 229960004373 acetylcholine Drugs 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 5
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- WJFXVTBMJUVLAX-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC(OC)=CC2=C1NCC2 WJFXVTBMJUVLAX-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AVRJTNMCEZERCF-UHFFFAOYSA-N 1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CCC1=COC2=CC=CC=C12 AVRJTNMCEZERCF-UHFFFAOYSA-N 0.000 description 2
- CZECZOSMTIPXNN-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC=CC=C2N1C=1C(=O)C(=O)C=1NCCN(CC1)CCC1COC1=CC=CC=C1 CZECZOSMTIPXNN-UHFFFAOYSA-N 0.000 description 2
- PJDYSZRGHQSZBE-UHFFFAOYSA-N 3-(4-chloroanilino)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(Cl)=CC=C1NC(C(C1=O)=O)=C1NCCN1CCC(COC=2C=CC=CC=2)CC1 PJDYSZRGHQSZBE-UHFFFAOYSA-N 0.000 description 2
- NJDRZHYOIXAFRO-UHFFFAOYSA-N 3-(4-fluoroanilino)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1NC(C(C1=O)=O)=C1NCCN1CCC(COC=2C=CC=CC=2)CC1 NJDRZHYOIXAFRO-UHFFFAOYSA-N 0.000 description 2
- WJNUYPWJAJTQNP-UHFFFAOYSA-N 3-anilino-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C=1C=CC=CC=1NC=1C(=O)C(=O)C=1NCCN(CC1)CCC1COC1=CC=CC=C1 WJNUYPWJAJTQNP-UHFFFAOYSA-N 0.000 description 2
- WRAADCZMKDEUSK-UHFFFAOYSA-N 4,5-dimethoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=C2NCCC2=C1OC WRAADCZMKDEUSK-UHFFFAOYSA-N 0.000 description 2
- YGIMZVANDAKRRB-UHFFFAOYSA-N 4,6-dimethoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC(OC)=CC2=C1CCN2 YGIMZVANDAKRRB-UHFFFAOYSA-N 0.000 description 2
- RVDBTIXYAAEUBY-UHFFFAOYSA-N 4-[[3,4-dioxo-2-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobuten-1-yl]amino]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1NC=1C(=O)C(=O)C=1NCCN(CC1)CCC1COC1=CC=CC=C1 RVDBTIXYAAEUBY-UHFFFAOYSA-N 0.000 description 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- VZBCMLFUMNFRJW-UHFFFAOYSA-N (5-methoxy-4-azabicyclo[4.2.0]octa-1(6),2,4,7-tetraen-7-yl)methanamine Chemical compound COC1=NC=CC2=C1C(CN)=C2 VZBCMLFUMNFRJW-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- FPDIGOXNBWROCV-UHFFFAOYSA-N 1-[3-[2-(3,4-difluorophenyl)ethoxy]propyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CCCOCCC1=CC=C(F)C(F)=C1 FPDIGOXNBWROCV-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FPBGOCRKUSNALR-UHFFFAOYSA-N 2-[4-(phenoxymethyl)piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1COC1=CC=CC=C1 FPBGOCRKUSNALR-UHFFFAOYSA-N 0.000 description 1
- SGRGFGXMJYHVHW-UHFFFAOYSA-N 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanamine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(CCN)CC1 SGRGFGXMJYHVHW-UHFFFAOYSA-N 0.000 description 1
- IDCUCQDXXWHJGM-UHFFFAOYSA-N 2-[4-[(4-fluorophenyl)methoxymethyl]piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1COCC1=CC=C(F)C=C1 IDCUCQDXXWHJGM-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- DFSFLZCLKYZYRD-UHFFFAOYSA-N 3,4-diethoxycyclobut-3-ene-1,2-dione Chemical compound CCOC1=C(OCC)C(=O)C1=O DFSFLZCLKYZYRD-UHFFFAOYSA-N 0.000 description 1
- FWGVNSNGMHPRKK-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)-4-[2-[4-[(4-fluorophenyl)methoxymethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1COCC1CCN(CCNC=2C(C(=O)C=2N2C3=CC=CC=C3CC2)=O)CC1 FWGVNSNGMHPRKK-UHFFFAOYSA-N 0.000 description 1
- YVNWXBXWQILYIR-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2N2C3=CC=CC=C3CC2)=O)CC1 YVNWXBXWQILYIR-UHFFFAOYSA-N 0.000 description 1
- IGPOTVQMMRBFHB-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)-4-[[1-[2-(1h-indol-3-yl)ethyl]piperidin-3-yl]methylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC=CC=C2N1C1=C(NCC2CN(CCC=3C4=CC=CC=C4NC=3)CCC2)C(=O)C1=O IGPOTVQMMRBFHB-UHFFFAOYSA-N 0.000 description 1
- UGVPUSNBNWYMGE-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)-4-ethoxycyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(OCC)=C1N1C2=CC=CC=C2CC1 UGVPUSNBNWYMGE-UHFFFAOYSA-N 0.000 description 1
- GQHUWGDQWRXIQK-UHFFFAOYSA-N 3-(4,5-dimethoxy-2,3-dihydroindol-1-yl)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC2=C(OC)C(OC)=CC=C2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1COC1=CC=CC=C1 GQHUWGDQWRXIQK-UHFFFAOYSA-N 0.000 description 1
- VGKXRVGAYXWPHV-UHFFFAOYSA-N 3-(4,5-dimethoxy-2,3-dihydroindol-1-yl)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC2=C(OC)C(OC)=CC=C2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 VGKXRVGAYXWPHV-UHFFFAOYSA-N 0.000 description 1
- JTVIKGXPVSWKCG-UHFFFAOYSA-N 3-(4,6-dimethoxy-2,3-dihydroindol-1-yl)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC=2C(OC)=CC(OC)=CC=2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1COC1=CC=CC=C1 JTVIKGXPVSWKCG-UHFFFAOYSA-N 0.000 description 1
- ZSSLRAGURCUEOS-UHFFFAOYSA-N 3-(4-chloroanilino)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2NC=2C=CC(Cl)=CC=2)=O)CC1 ZSSLRAGURCUEOS-UHFFFAOYSA-N 0.000 description 1
- WHMDUVQHBBKIIM-UHFFFAOYSA-N 3-(4-chloroanilino)-4-ethoxycyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(OCC)=C1NC1=CC=C(Cl)C=C1 WHMDUVQHBBKIIM-UHFFFAOYSA-N 0.000 description 1
- VIUSNRBIJBVZSJ-UHFFFAOYSA-N 3-(5-chloro-2,3-dihydroindol-1-yl)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2N2C3=CC=C(Cl)C=C3CC2)=O)CC1 VIUSNRBIJBVZSJ-UHFFFAOYSA-N 0.000 description 1
- ROSXLIHAHGALBB-UHFFFAOYSA-N 3-(5-fluoro-2,3-dihydroindol-1-yl)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2N2C3=CC=C(F)C=C3CC2)=O)CC1 ROSXLIHAHGALBB-UHFFFAOYSA-N 0.000 description 1
- LHRGVGMEAXFEHY-UHFFFAOYSA-N 3-(6,7-dihydro-[1,3]dioxolo[4,5-f]indol-5-yl)-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC=3OCOC=3C=C2N1C=1C(=O)C(=O)C=1NCCN(CC1)CCC1COC1=CC=CC=C1 LHRGVGMEAXFEHY-UHFFFAOYSA-N 0.000 description 1
- KBYVIUHSEMKTAO-UHFFFAOYSA-N 3-(6-chloro-2,3-dihydroindol-1-yl)-4-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2N2C3=CC(Cl)=CC=C3CC2)=O)CC1 KBYVIUHSEMKTAO-UHFFFAOYSA-N 0.000 description 1
- GIGXYHGYSXMOGC-UHFFFAOYSA-N 3-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]-4-[2-[4-(phenoxymethyl)piperidin-1-yl]ethylamino]cyclobut-3-ene-1,2-dione Chemical compound C=1C=C2NC(=O)NC2=CC=1NC=1C(=O)C(=O)C=1NCCN(CC1)CCC1COC1=CC=CC=C1 GIGXYHGYSXMOGC-UHFFFAOYSA-N 0.000 description 1
- BNADCIUSVMSGHH-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(4,5,6-trimethoxy-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1CC=2C(OC)=C(OC)C(OC)=CC=2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 BNADCIUSVMSGHH-UHFFFAOYSA-N 0.000 description 1
- PCPCKHIFPBJDRX-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(4,5,6-trimethoxy-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione dihydrochloride Chemical compound FC1=CC=C(OCCC2CCN(CC2)CCNC=2C(C(C2N2CCC3=C(C(=C(C=C23)OC)OC)OC)=O)=O)C=C1.Cl.Cl PCPCKHIFPBJDRX-UHFFFAOYSA-N 0.000 description 1
- YRKAEGMCESQJJU-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(4-methoxy-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1CC=2C(OC)=CC=CC=2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 YRKAEGMCESQJJU-UHFFFAOYSA-N 0.000 description 1
- ZOKXISYGBIOBLN-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(4-nitroanilino)cyclobut-3-ene-1,2-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(C(C1=O)=O)=C1NCCN1CCC(CCOC=2C=CC(F)=CC=2)CC1 ZOKXISYGBIOBLN-UHFFFAOYSA-N 0.000 description 1
- QDPCXYNUOPNMBA-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(5-methoxy-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC(OC)=CC=C2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 QDPCXYNUOPNMBA-UHFFFAOYSA-N 0.000 description 1
- SEHABBPMUSGROY-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(5-methoxy-2,3-dihydropyrrolo[2,3-c]pyridin-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1=2C=NC(OC)=CC=2CCN1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 SEHABBPMUSGROY-UHFFFAOYSA-N 0.000 description 1
- ZESJZZZJMJVYLC-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(5-nitro-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC([N+](=O)[O-])=CC=C2N1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 ZESJZZZJMJVYLC-UHFFFAOYSA-N 0.000 description 1
- QLDYIMIXZXXZAE-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-(6-methoxy-2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C12=CC(OC)=CC=C2CCN1C(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 QLDYIMIXZXXZAE-UHFFFAOYSA-N 0.000 description 1
- YOMNSEPHMUUPRQ-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCNC=2C(C(=O)C=2NC=2C=C3NC(=O)NC3=CC=2)=O)CC1 YOMNSEPHMUUPRQ-UHFFFAOYSA-N 0.000 description 1
- WWBUZPSDZMHXMY-UHFFFAOYSA-N 3-[2-[4-[2-(4-fluorophenoxy)ethyl]piperidin-1-yl]ethylamino]-4-[(5-methoxy-4-azabicyclo[4.2.0]octa-1(8),2,4,6-tetraen-7-yl)methylamino]cyclobut-3-ene-1,2-dione Chemical compound C=12C(OC)=NC=CC2=CC=1CNC(C(C1=O)=O)=C1NCCN(CC1)CCC1CCOC1=CC=C(F)C=C1 WWBUZPSDZMHXMY-UHFFFAOYSA-N 0.000 description 1
- ZGLAIMXKRYVBHJ-UHFFFAOYSA-N 3-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]-4-(2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1CC2=CC=CC=C2N1C1=C(NC2CCN(CCC=3C4=CC=CC=C4OC=3)CC2)C(=O)C1=O ZGLAIMXKRYVBHJ-UHFFFAOYSA-N 0.000 description 1
- IULFCDYQCNUCND-UHFFFAOYSA-N 3-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]-4-(4-chloroanilino)cyclobut-3-ene-1,2-dione Chemical compound C1=CC(Cl)=CC=C1NC(C(C1=O)=O)=C1NC1CCN(CCC=2C3=CC=CC=C3OC=2)CC1 IULFCDYQCNUCND-UHFFFAOYSA-N 0.000 description 1
- MYFPNZDFVUDHBA-UHFFFAOYSA-N 3-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]-4-(4-fluoroanilino)cyclobut-3-ene-1,2-dione Chemical compound C1=CC(F)=CC=C1NC(C(C1=O)=O)=C1NC1CCN(CCC=2C3=CC=CC=C3OC=2)CC1 MYFPNZDFVUDHBA-UHFFFAOYSA-N 0.000 description 1
- ZGNZJRJPPOUVIR-UHFFFAOYSA-N 3-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]-4-(5-methoxy-2,3-dihydropyrrolo[2,3-c]pyridin-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1=CC=C2C(CCN3CCC(CC3)NC3=C(C(C3=O)=O)N3CCC=4C=C(N=CC=43)OC)=COC2=C1 ZGNZJRJPPOUVIR-UHFFFAOYSA-N 0.000 description 1
- IGEKOOFOUMKCSD-UHFFFAOYSA-N 3-[[1-[3-[2-(3,4-difluorophenyl)ethoxy]propyl]piperidin-4-yl]amino]-4-(2,3-dihydroindol-1-yl)cyclobut-3-ene-1,2-dione Chemical compound C1=C(F)C(F)=CC=C1CCOCCCN1CCC(NC=2C(C(=O)C=2N2C3=CC=CC=C3CC2)=O)CC1 IGEKOOFOUMKCSD-UHFFFAOYSA-N 0.000 description 1
- IOMFAUBPEKWHEE-UHFFFAOYSA-N 3-anilino-4-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]cyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(NC2CCN(CCC=3C4=CC=CC=C4OC=3)CC2)=C1NC1=CC=CC=C1 IOMFAUBPEKWHEE-UHFFFAOYSA-N 0.000 description 1
- WJHCIIWYNPNBMY-UHFFFAOYSA-N 3-anilino-4-ethoxycyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(OCC)=C1NC1=CC=CC=C1 WJHCIIWYNPNBMY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KOSTTZDXKBRMCR-UHFFFAOYSA-N 3-ethoxy-4-(4-fluoroanilino)cyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(OCC)=C1NC1=CC=C(F)C=C1 KOSTTZDXKBRMCR-UHFFFAOYSA-N 0.000 description 1
- YDPQRCDAQLYQFO-UHFFFAOYSA-N 4,5,6-trimethoxy-2,3-dihydro-1h-indole Chemical compound COC1=C(OC)C(OC)=CC2=C1CCN2 YDPQRCDAQLYQFO-UHFFFAOYSA-N 0.000 description 1
- UFRUQPGNYQRKLS-UHFFFAOYSA-N 4-[(2-ethoxy-3,4-dioxocyclobuten-1-yl)amino]benzonitrile Chemical compound O=C1C(=O)C(OCC)=C1NC1=CC=C(C#N)C=C1 UFRUQPGNYQRKLS-UHFFFAOYSA-N 0.000 description 1
- MCCYLASHPFWRPT-UHFFFAOYSA-N 4-[[2-[[1-[2-(1-benzofuran-3-yl)ethyl]piperidin-4-yl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzonitrile Chemical compound O=C1C(=O)C(NC2CCN(CCC=3C4=CC=CC=C4OC=3)CC2)=C1NC1=CC=C(C#N)C=C1 MCCYLASHPFWRPT-UHFFFAOYSA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- MIOTXFNRNVNXDP-UHFFFAOYSA-N 4-methoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=CC2=C1CCN2 MIOTXFNRNVNXDP-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- DPRMKYPHVPDUIH-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydro-1h-indole Chemical compound C1=C(OC)C(OC)=CC2=C1NCC2 DPRMKYPHVPDUIH-UHFFFAOYSA-N 0.000 description 1
- BCXSVFBDMPSKPT-UHFFFAOYSA-N 5-amino-1,3-dihydrobenzimidazol-2-one Chemical compound NC1=CC=C2NC(=O)NC2=C1 BCXSVFBDMPSKPT-UHFFFAOYSA-N 0.000 description 1
- YMCIVAPEOZDEGH-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1h-indole Chemical compound ClC1=CC=C2NCCC2=C1 YMCIVAPEOZDEGH-UHFFFAOYSA-N 0.000 description 1
- NXQRMQIYCWFDGP-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1h-indole Chemical compound FC1=CC=C2NCCC2=C1 NXQRMQIYCWFDGP-UHFFFAOYSA-N 0.000 description 1
- YYDYAQAVAHKFJO-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=C2NCCC2=C1 YYDYAQAVAHKFJO-UHFFFAOYSA-N 0.000 description 1
- WJQWYAJTPPYORB-UHFFFAOYSA-N 5-nitro-2,3-dihydro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NCCC2=C1 WJQWYAJTPPYORB-UHFFFAOYSA-N 0.000 description 1
- QXSXUCFIJKIEJX-UHFFFAOYSA-N 6,7-dihydro-5h-[1,3]dioxolo[4,5-f]indole Chemical compound C1=C2NCCC2=CC2=C1OCO2 QXSXUCFIJKIEJX-UHFFFAOYSA-N 0.000 description 1
- HSLNYVREDLDESE-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1h-indole Chemical compound ClC1=CC=C2CCNC2=C1 HSLNYVREDLDESE-UHFFFAOYSA-N 0.000 description 1
- GKFGHNMPMAXWQS-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=C2CCNC2=C1 GKFGHNMPMAXWQS-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- DIQPXJFUVRTBEH-UHFFFAOYSA-N COC=1C=C2C(=CN1)N(CC2)C=2C(C(C2NCCN2CCC(CC2)COC2=CC=CC=C2)=O)=O.CS(=O)(=O)O Chemical compound COC=1C=C2C(=CN1)N(CC2)C=2C(C(C2NCCN2CCC(CC2)COC2=CC=CC=C2)=O)=O.CS(=O)(=O)O DIQPXJFUVRTBEH-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- VMVQTFMHACWGTQ-UHFFFAOYSA-N [1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methanamine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CC(CN)CCC1 VMVQTFMHACWGTQ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000006493 arterial relaxation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- RGBVWCQARBEPPW-UHFFFAOYSA-N cyclobut-3-ene-1,2-dione Chemical class O=C1C=CC1=O RGBVWCQARBEPPW-UHFFFAOYSA-N 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0013072A FR2815345B1 (fr) | 2000-10-12 | 2000-10-12 | Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014945D0 NO20014945D0 (no) | 2001-10-11 |
| NO20014945L NO20014945L (no) | 2002-04-15 |
| NO320702B1 true NO320702B1 (no) | 2006-01-16 |
Family
ID=8855275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014945A NO320702B1 (no) | 2000-10-12 | 2001-10-11 | Nye cyklonbutendionforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6696469B2 (es) |
| EP (1) | EP1197485B1 (es) |
| JP (1) | JP3566685B2 (es) |
| KR (1) | KR100511132B1 (es) |
| CN (1) | CN1274675C (es) |
| AR (1) | AR033683A1 (es) |
| AT (1) | ATE273276T1 (es) |
| AU (1) | AU781002B2 (es) |
| BR (1) | BR0104471A (es) |
| CA (1) | CA2358724C (es) |
| DE (1) | DE60104791T2 (es) |
| DK (1) | DK1197485T3 (es) |
| EA (1) | EA004268B1 (es) |
| ES (1) | ES2227092T3 (es) |
| FR (1) | FR2815345B1 (es) |
| HK (1) | HK1045517B (es) |
| HU (1) | HUP0104272A3 (es) |
| MX (1) | MXPA01010049A (es) |
| NO (1) | NO320702B1 (es) |
| NZ (1) | NZ514758A (es) |
| PL (1) | PL350104A1 (es) |
| PT (1) | PT1197485E (es) |
| SI (1) | SI1197485T1 (es) |
| TR (1) | TR200402070T4 (es) |
| ZA (1) | ZA200108404B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009734A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| NZ552093A (en) | 2004-06-17 | 2009-06-26 | Wyeth Corp | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| WO2006058012A2 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| ES2327840T3 (es) * | 2004-12-23 | 2009-11-04 | Gpc Biotech Ag | Derivados de acido escuarico con actividad antiproliferativa. |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| EP2318369A1 (en) | 2008-06-24 | 2011-05-11 | TopoTarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| EP2760821B1 (en) | 2011-09-02 | 2017-10-11 | Novartis AG | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105377B1 (en) * | 1998-08-21 | 2003-10-08 | SmithKline Beecham plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
| BR9916211A (pt) * | 1998-12-14 | 2001-09-11 | American Home Prod | Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesão de leucócito mediada por vla-4 |
| US6432960B2 (en) * | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
-
2000
- 2000-10-12 FR FR0013072A patent/FR2815345B1/fr not_active Expired - Fee Related
-
2001
- 2001-10-05 MX MXPA01010049A patent/MXPA01010049A/es active IP Right Grant
- 2001-10-09 BR BR0104471-0A patent/BR0104471A/pt not_active IP Right Cessation
- 2001-10-09 JP JP2001311565A patent/JP3566685B2/ja not_active Expired - Fee Related
- 2001-10-11 NO NO20014945A patent/NO320702B1/no not_active IP Right Cessation
- 2001-10-11 PT PT01402623T patent/PT1197485E/pt unknown
- 2001-10-11 DK DK01402623T patent/DK1197485T3/da active
- 2001-10-11 NZ NZ514758A patent/NZ514758A/xx unknown
- 2001-10-11 SI SI200130164T patent/SI1197485T1/xx unknown
- 2001-10-11 DE DE60104791T patent/DE60104791T2/de not_active Expired - Fee Related
- 2001-10-11 EP EP01402623A patent/EP1197485B1/fr not_active Expired - Lifetime
- 2001-10-11 CA CA002358724A patent/CA2358724C/fr not_active Expired - Fee Related
- 2001-10-11 AR ARP010104769A patent/AR033683A1/es unknown
- 2001-10-11 ES ES01402623T patent/ES2227092T3/es not_active Expired - Lifetime
- 2001-10-11 AT AT01402623T patent/ATE273276T1/de not_active IP Right Cessation
- 2001-10-11 TR TR2004/02070T patent/TR200402070T4/xx unknown
- 2001-10-12 AU AU79386/01A patent/AU781002B2/en not_active Ceased
- 2001-10-12 HU HU0104272A patent/HUP0104272A3/hu unknown
- 2001-10-12 ZA ZA200108404A patent/ZA200108404B/xx unknown
- 2001-10-12 PL PL01350104A patent/PL350104A1/xx not_active Application Discontinuation
- 2001-10-12 US US09/976,572 patent/US6696469B2/en not_active Expired - Fee Related
- 2001-10-12 EA EA200100969A patent/EA004268B1/ru unknown
- 2001-10-12 CN CNB011412968A patent/CN1274675C/zh not_active Expired - Fee Related
- 2001-10-12 KR KR10-2001-0062988A patent/KR100511132B1/ko not_active IP Right Cessation
-
2002
- 2002-09-26 HK HK02107053.7A patent/HK1045517B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320702B1 (no) | Nye cyklonbutendionforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| WO2005082367A1 (en) | Kinase inhibitors | |
| ZA200502009B (en) | 1-Pyridiin-4-yl-urea derivatives. | |
| US6323217B2 (en) | Piperidine-4 sulphonamide compounds | |
| ES2280482T3 (es) | Ureas lineales o ciclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| AU2004202768B2 (en) | New linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | |
| US20070010516A1 (en) | Novel piperidine derivatives | |
| JP2006052181A (ja) | 新規なキノリン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |